KLCM Advisors’s ImmunityBio IBRX Stock Holding History

KLCM Advisors’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$254K	Hold	29,000	–	–	0.02%	244
2026 Q1	$222K	Buy	+29,000	New	+$199K	0.02%	241

Other funds holding IBRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

KLCM Advisors's IBRX Position: Q2 2026 in Review

KLCM Advisors held its ImmunityBio (IBRX) position steady in Q2 2026 at 29,000 shares worth $254K. The position accounts for 0.02% of the portfolio, ranked #244.

KLCM Advisors first reported a position in IBRX in Q1 2026 and has held it in 2 quarters since. 405 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

KLCM Advisors held 29,000 shares of ImmunityBio worth $254K as of Q2 2026.
KLCM Advisors left its ImmunityBio share count unchanged in Q2 2026.
ImmunityBio made up 0.02% of KLCM Advisors's portfolio in Q2 2026, its #244 holding.
KLCM Advisors first reported a position in ImmunityBio in Q1 2026 and has held it in 2 quarters since.
405 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on KLCM Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.